| disitamab vedotin | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Phase 3 | Active not recruiting | 412 | Jan 29, 2027 |
| Abrysvo | Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. | Phase 3 | Active not recruiting | 38,861 | Jan 18, 2027 |
| Talzenna | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | Phase 3 | Active not recruiting | 77 | Dec 31, 2026 |
| PF-07104091 monotherapy dose escalation | PF-07104091 as a Single Agent and in Combination Therapy | Phase 2 | Active not recruiting | 157 | Dec 31, 2026 |
| Vepdegestrant (ARV-471/PF-07850327) | Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | Phase 3 | Active not recruiting | 59 | Dec 30, 2026 |
| Xtandi | A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | Phase 3 | Active not recruiting | 600 | Dec 28, 2026 |
| Litfulo | A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. | Phase 2 | Active not recruiting | 128 | Dec 8, 2026 |
| Ritlecitinib higher dose | A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | Phase 3 | Active not recruiting | 208 | Dec 2, 2026 |
| PF-07868489 | A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489 | Phase 2 | Terminated | 42 | Oct 9, 2026 |
| ARV-471 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) | Phase 2 | Terminated | 20 | Oct 6, 2026 |
| MET233 and MET097 | A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes | Phase 2 | Completed | 201 | Sep 29, 2026 |
| PF-06835375 | Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia | Phase 2 | Terminated | 61 | Sep 23, 2026 |
| Folic Acid | Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy | Phase 2 | Completed | 84 | Sep 22, 2026 |
| vepdegestrant | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) | Phase 2 | Terminated | 11 | Sep 10, 2026 |
| ARV-471 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) | Phase 2 | Active not recruiting | 37 | Sep 1, 2026 |
| Abrysvo | A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease. | Phase 3 | Completed | 130 | Aug 25, 2026 |
| PF-07220060 + PF-07104091 combination dose escalation | A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors | Phase 2 | Active not recruiting | 192 | Aug 23, 2026 |
| Oxaliplatin | XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC) | Phase 3 | Completed | 1,024 | Aug 15, 2026 |
| Doxorubicin | Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | Phase 2 | Completed | 30 | Aug 4, 2026 |
| PF-07868489 | A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension | Phase 2 | Completed | 97 | Jul 31, 2026 |
| PF-06838435 (formerly SPK-9001) | Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B | Phase 2 | Terminated | 21 | Jul 23, 2026 |
| HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin | D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma | Phase 3 | Completed | 367 | Jun 30, 2026 |
| 2.5% Diclofenac Patches | Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis | Phase 2 | Completed | 307 | Jun 26, 2026 |
| Ketamine only | Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19 | Phase 2 | Completed | 20 | Jun 22, 2026 |
| Bupivacaine | A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation | Phase 3 | Completed | 200 | Jun 8, 2026 |
| Braftovi | A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer | Phase 2 | Active not recruiting | 107 | Jun 1, 2026 |
| Carboplatin | Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer | Phase 2 | Terminated · results | 31 | Jun 1, 2026 |
| disitamab vedotin | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | Phase 2 | Active not recruiting | 120 | May 31, 2026 |
| Lidocaine cream and general advice | Pulsed Electromagnetic Field on Chronic Anal Fissure Healing | Phase 3 | Completed | 100 | May 22, 2026 |
| AK112 | A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | Phase 2 | Active not recruiting | 254 | May 15, 2026 |
| Multivalent Pneumococcal Vaccine - Formulation 1 | A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults | Phase 2 | Completed | 1,710 | May 12, 2026 |
| Xeljanz | Therapies for Down Syndrome Regression Disorder | Phase 2 | Completed | 66 | May 5, 2026 |
| Ketamine | Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV | Phase 2 | Completed | 17 | May 5, 2026 |
| Digoxin | Trial of Oral Digoxin in Individuals With Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Completed | 41 | Apr 13, 2026 |
| Litfulo | Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission | Phase 2 | Completed | 62 | Apr 9, 2026 |
| Carboplatin | Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. | Phase 2 | Completed | 117 | Apr 9, 2026 |
| maplirpacept (PF-07901801) | A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. | Phase 2 | Terminated | 40 | Apr 9, 2026 |
| Tisotumab Vedotin | Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer | Phase 2 | Terminated | 214 | Mar 19, 2026 |
| 0.5% Bupivacaine HCl | The Anesthetic and Analgesic Effect of Adjunct Liposomal Bupivacaine in Periodontal Surgical Procedures | Phase 2 | Completed | 58 | Mar 15, 2026 |